We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
SALTRO Launches Directlab, A Web-Based Service
News

SALTRO Launches Directlab, A Web-Based Service

SALTRO Launches Directlab, A Web-Based Service
News

SALTRO Launches Directlab, A Web-Based Service

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "SALTRO Launches Directlab, A Web-Based Service"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Novosanis announced their collaboration with Saltro, an innovative diagnostic center with headquarters in Utrecht, The Netherlands. ‘Directlab’ is Saltro’s initiative to provide a better and easy accessible program to test for STIs (Sexual Transmitted Infections). Saltro chose Novosanis’ Colli-Pee™ to ensure standardized first-void urine (first 20ml of urine) self-sampling.

The first test Saltro’s Directlab offers is a Chlamydia test. Although a Chlamydia infection does not cause significant problems in the beginning it can cause complications and is highly transmittable. Therefore easy access to detect the bacteria and drive the patient to a GP for treatment is key in the prevention of spreading.

Unique to this initiative is the possibility for home-based self-sampling in an easy and first-time right manner. Novosanis Colli-Pee offers the solution to collect first-void urine that can be send to the lab for analysis. This way the quality of the test is guaranteed while providing the patient the needed discretion in order to motivate him or her to take the test.

Vanessa Vankerckhoven, CEO Novosanis stated: “We are pleased that Colli-Pee is part of a disruptive new solution offering home-based self-sampling for detection of STIs. We are convinced that public health will benefit from Saltro’s Directlab initiative. ”

“The advantage of inclusion Colli-Pee is that it provides a standardized first-void sample which will be beneficial for the analysis of STIs. Moreover the device can easily be shipped by postal mail to the patients’ home.” says Dr. Sanne van Delft, Program manager at Saltro.

Advertisement